drugset / Trial / NCT05097209
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
Phase 2
Unknown
200 enrolled
Wei Jiang
Guangxi Nanxishan Hospital · collabLaibin People's Hospital · collabLingshan people's Hospital · collabWuzhou Red Cross Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial plans to enroll patients with stage III-IVA (AJCC 8th, included T1-2N2-3 and/or T3-4N0-3 M0) locoregionally-advanced nasopharyngeal carcinoma (LANPC). Patients will be randomized in a 1:1 ratio to receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation or 3 cycles of induction chemotherapy with gemcitabine and cisplatin and radiation plus Camrelizumab. All patients will receive intensity-modulated radiotherapy (IMRT). Camrelizumab will begin on day 1 of induction chemotherapy every 3 weeks for 3 cycles and continue every 2 weeks for 9 cycles.
Timeline
- Start
- 2022-04-06
- Primary completion
- 2025-04-06
- Completion
- 2026-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 100 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |